MX364495B - Composición para usarse en el tratamiento de enfermedades oculares relacionadas con ácidos nucleicos. - Google Patents

Composición para usarse en el tratamiento de enfermedades oculares relacionadas con ácidos nucleicos.

Info

Publication number
MX364495B
MX364495B MX2014007103A MX2014007103A MX364495B MX 364495 B MX364495 B MX 364495B MX 2014007103 A MX2014007103 A MX 2014007103A MX 2014007103 A MX2014007103 A MX 2014007103A MX 364495 B MX364495 B MX 364495B
Authority
MX
Mexico
Prior art keywords
composition
nucleic acid
eye disease
related eye
treating nucleic
Prior art date
Application number
MX2014007103A
Other languages
English (en)
Other versions
MX2014007103A (es
Inventor
Jain Sandeep
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MX2014007103A publication Critical patent/MX2014007103A/es
Publication of MX364495B publication Critical patent/MX364495B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Eyeglasses (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición para usarse en el tratamiento de una enfermedad ocular relacionada con ácido nucleico, en donde la composición comprende una nucleasa y un excipiente, oftálmico; en donde la nucleasa es seleccionada del grupo consistente de Desoxirribonucleasa I (ADNasa I), Desoxirribonucleasa II (ADNasa II) , Desoxirribonucleasa III (ADNasa III), nucleasa micrococal y una ADNasa recombinante; y en donde la enfermedad ocular relacionada con ácido nucleico es seleccionada del grupo que consiste de la enfermedad de ojo seco, queratitis, laminar, queratitis asociada con lente de contacto, endoftalmitis, querotapatía cristalina infecciosa, pénfigo de cicatrización ocular (OCP), queratoconjuntivitis seca (Kcs), síndrome de Sjögren, queratoconjuntivitis seca asocaiada con síndrome de no Sjögren, queratitis seca, síndrome seco, xeroftalmia, trastorno de película lagrimal, producción disminuida de lágrimas, difidencia lagrimal acuosa (ATD), una infección bacteriana ocular y disfunción de la glándula de Meibomio (MGD).
MX2014007103A 2011-12-12 2012-08-20 Composición para usarse en el tratamiento de enfermedades oculares relacionadas con ácidos nucleicos. MX364495B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161569604P 2011-12-12 2011-12-12
US201261600377P 2012-02-17 2012-02-17
PCT/US2012/051562 WO2013089835A1 (en) 2011-12-12 2012-08-20 Composition and method for treating nucleic acid-related eye disease

Publications (2)

Publication Number Publication Date
MX2014007103A MX2014007103A (es) 2015-05-11
MX364495B true MX364495B (es) 2019-04-29

Family

ID=48613071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007103A MX364495B (es) 2011-12-12 2012-08-20 Composición para usarse en el tratamiento de enfermedades oculares relacionadas con ácidos nucleicos.

Country Status (15)

Country Link
US (3) US9867871B2 (es)
EP (1) EP2790722B1 (es)
JP (1) JP6202400B2 (es)
KR (1) KR101898438B1 (es)
CN (1) CN104220087A (es)
AU (1) AU2012352983B2 (es)
BR (1) BR112014014378A2 (es)
CA (1) CA2858983C (es)
DK (1) DK2790722T3 (es)
ES (1) ES2713519T3 (es)
IL (1) IL232999B (es)
MX (1) MX364495B (es)
RU (1) RU2642609C2 (es)
WO (1) WO2013089835A1 (es)
ZA (1) ZA201404320B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2847215A1 (en) * 2012-05-07 2015-03-18 Synthes GmbH Methods and devices for treating intervertebral disc disease
US9919034B2 (en) 2014-03-28 2018-03-20 Tamir Biotechnology, Inc. Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
US10835598B2 (en) 2014-08-18 2020-11-17 Orgenesis Inc. Prophylactic protection against viral infections, particularly HIV
US10293032B2 (en) * 2015-06-15 2019-05-21 Tamir Biotechnology, Inc. Methods and pharmaceuticals for treatment of viral infections of the eye
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
US11058713B2 (en) * 2017-06-29 2021-07-13 Advaite LLC. Treatment and diagnosis of ocular surface disorders
AU2018318313B2 (en) 2017-08-18 2025-01-23 Neutrolis Inc. Engineered DNase enzymes and use in therapy
TW201920956A (zh) * 2017-09-29 2019-06-01 日商參天製藥股份有限公司 淚液中之muc5ac量之測定方法
US11464672B2 (en) 2018-06-01 2022-10-11 Aurora Tears Technology, Inc. Systems and methods for generating and applying biomimicry tear films
US11253395B2 (en) * 2018-06-01 2022-02-22 Aurora Tears Technology, Inc. Systems and methods for generating and applying biomimicry tear films
US12558258B2 (en) 2018-06-01 2026-02-24 Aurora Tears Technology, Inc. Systems and methods for administering fluid compositions
US10988746B2 (en) 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
US11058724B2 (en) 2018-10-08 2021-07-13 Neutrolis, Inc. Methods of using DNASE1-like 3 in therapy
WO2020076817A1 (en) 2018-10-08 2020-04-16 Neutrolis, Inc. Engineering of dnase enzymes for manufacturing and therapy
US11352613B2 (en) 2019-02-04 2022-06-07 Neutrolis, Inc. Engineered human extracellular DNASE enzymes
CN112004650A (zh) 2019-03-25 2020-11-27 宝洁公司 多层可溶解固体制品及其制备方法
WO2021077367A1 (en) 2019-10-24 2021-04-29 The Procter & Gamble Company Multilayer dissolvable solid article containing coating composition and process for making the same
RU2740363C1 (ru) * 2020-08-03 2021-01-13 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ оценки эффективности лечения синдрома сухого глаза у больных сахарным диабетом
BE1028712B1 (fr) 2020-10-16 2022-05-18 Onelife S A Composition para-pharmaceutique ou pharmaceutique administrable à un être vivant, de préférence un être humain comprenant au moins une enzyme pour le traitement et/ou la prévention d'infections bactériennes impliquant la formation de biofilm
CN115595315B (zh) * 2021-06-28 2024-08-16 四川大学华西医院 核糖核酸酶i在抑制疼痛的药物中的新用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1575359A1 (ru) 1988-06-14 1991-05-15 Институт Морфологии Человека Амн Ссср Способ получени рибонуклеотидов
DE69838452T2 (de) 1997-07-29 2008-06-12 The Solution Line, Inc., Lebanon Stift aus regeneriertem kautschuk
GB9716376D0 (en) * 1997-08-01 1997-10-08 Isis Innovation Artificial tear formulation
US6759040B1 (en) * 1997-09-12 2004-07-06 University Of Maryland, College Park Preparation and use of biofilm-degrading, multiple-specificity, hydrolytic enzyme mixtures
US20080096817A1 (en) 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
AU3664102A (en) * 2000-12-01 2002-06-11 Battelle Memorial Institute Method for stabilizing biomolecules in liquid formulations
CN101195025A (zh) 2001-03-15 2008-06-11 雷金纳克斯生物制药公司 胸腺素β4、类似物、异构体及其它衍生物在制备治疗眼睛和周围组织失调的药物中的应用
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050089546A1 (en) 2003-09-16 2005-04-28 Dick Wurtman Compositions and methods comprising complex carbohydrate and alpha-lactalbumin
EP1753445A4 (en) 2004-05-06 2009-05-20 Molichem Medicines Inc TREATMENT OF EYE DISEASES AND EYE TREATMENTS WITH LANTIBIOTIC COMPOSITIONS
US20080233053A1 (en) 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
US20080139545A1 (en) * 2006-05-22 2008-06-12 Won-Taek Choe Formulation to treat ear infection
CA2713977A1 (en) * 2007-02-15 2008-08-21 National Jewish Medical And Research Center Methods and compositions for the disruption of biofilms
WO2009002790A2 (en) * 2007-06-26 2008-12-31 Bausch & Lomb Incorporated Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
TW200927192A (en) 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
GB2477914B (en) * 2010-02-12 2012-01-04 Univ Newcastle Compounds and methods for biofilm disruption and prevention

Also Published As

Publication number Publication date
CA2858983A1 (en) 2013-06-20
CN104220087A (zh) 2014-12-17
JP6202400B2 (ja) 2017-09-27
WO2013089835A1 (en) 2013-06-20
RU2642609C2 (ru) 2018-01-25
US9867871B2 (en) 2018-01-16
US20170106057A1 (en) 2017-04-20
RU2014128564A (ru) 2016-02-10
US20150010524A1 (en) 2015-01-08
US10328129B2 (en) 2019-06-25
DK2790722T3 (en) 2019-03-25
AU2012352983A1 (en) 2014-07-03
EP2790722A4 (en) 2015-09-09
US20190314461A1 (en) 2019-10-17
ES2713519T3 (es) 2019-05-22
IL232999A0 (en) 2014-07-31
IL232999B (en) 2019-03-31
CA2858983C (en) 2020-06-09
MX2014007103A (es) 2015-05-11
BR112014014378A2 (pt) 2020-05-19
ZA201404320B (en) 2015-11-25
EP2790722A1 (en) 2014-10-22
EP2790722B1 (en) 2018-12-05
KR101898438B1 (ko) 2018-09-14
US11376312B2 (en) 2022-07-05
KR20140101857A (ko) 2014-08-20
JP2015506920A (ja) 2015-03-05
AU2012352983B2 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
MX364495B (es) Composición para usarse en el tratamiento de enfermedades oculares relacionadas con ácidos nucleicos.
EP2760359A4 (en) METHOD FOR TREATING EYE STATES
EP2753275A4 (en) METHODS OF TREATING OCULAR CONDITIONS
EP2757887A4 (en) PYRROLOPYRIDINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF HIV
EP2701498A4 (en) SYSTEM FOR COMBATING MALES AND CORRESPONDING METHOD FOR COMBATING MALES
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
EP2667823A1 (en) Coaptation enhancement implant, system, and method
ZA201400005B (en) Method for treating eczema
FI20116228A7 (fi) Menetelmä tuhkan, erityisesti lentotuhkan käsittelemiseksi
ZA201208219B (en) Method for treating wasterwater
BR112014004192A2 (pt) composição de tratamento de sementes, e, método de tratamento de sementes
EP2687705A4 (en) MOTOR CONTROL DEVICE AND MOTOR CONTROL METHOD
HUE044650T2 (hu) Eljárás EFP kezelésére vagy csökkentésére
BR112013022820A2 (pt) método de tratamento
BR112014016108A2 (pt) método de tratamento de perda óssea alvelar
IL260077A (en) Methods of treating excess bilirubin in the blood with stanoporfin
SG11201401981TA (en) Methods for treating gout flares
SG10201703677VA (en) Methods of treating s. aureus-associated diseases
ZA201408975B (en) Method of treating scedosporium spp. infection
ZA201403739B (en) Methods of treatment with deferiprone
PL2691219T3 (pl) Sposób obróbki tekstyliów technicznych
EP2673096A2 (en) Method of treating waste items
EP2690536A4 (en) INFORMATION PROCESSING DEVICE, ITS CONTROL METHOD, AND ASSOCIATED PROGRAM
HRP20130367T1 (hr) Postupak za preradu kože
HUE038149T2 (hu) Eljárás acél kezelésére

Legal Events

Date Code Title Description
FG Grant or registration